These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 37936687)

  • 21. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.
    Shimizu T; Seto T; Hirai F; Takenoyama M; Nosaki K; Tsurutani J; Kaneda H; Iwasa T; Kawakami H; Noguchi K; Shimamoto T; Nakagawa K
    Invest New Drugs; 2016 Jun; 34(3):347-54. PubMed ID: 27000274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.
    Qiu MZ; Zhang Y; Guo Y; Guo W; Nian W; Liao W; Xu Z; Zhang W; Zhao HY; Wei X; Xue L; Tang W; Wu Y; Ren G; Wang L; Xi J; Jin Y; Li H; Hu C; Xu RH
    JAMA Oncol; 2022 Jul; 8(7):1042-1046. PubMed ID: 35511148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors.
    Shitara K; Satoh T; Iwasa S; Yamaguchi K; Muro K; Komatsu Y; Nishina T; Esaki T; Hasegawa J; Kakurai Y; Kamiyama E; Nakata T; Nakamura K; Sakaki H; Hyodo I
    J Immunother Cancer; 2019 Aug; 7(1):219. PubMed ID: 31412935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.
    Tran B; Carvajal RD; Marabelle A; Patel SP; LoRusso PM; Rasmussen E; Juan G; Upreti VV; Beers C; Ngarmchamnanrith G; Schöffski P
    J Immunother Cancer; 2018 Sep; 6(1):93. PubMed ID: 30253804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
    Zhang Q; Zhang J; Zhong H; Yuan Y; Yang L; Zhang Q; Ji D; Gong J; Li J; Yao Z; Qi C; Wang J; Lu L; Shi M; Qian X; Shen L; Li J; Hu X
    Cancer Immunol Immunother; 2023 Aug; 72(8):2729-2739. PubMed ID: 37115210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors.
    Liu R; Li W; Meng Y; Gao S; Zhang J; Hu X
    Ther Adv Med Oncol; 2021; 13():17588359211020528. PubMed ID: 34158838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.
    Zhao Y; Ma Y; Zang A; Cheng Y; Zhang Y; Wang X; Chen Z; Qu S; He J; Chen C; Jin C; Zhu D; Li Q; Liu X; Su W; Ba Y; Hao Y; Chen J; Zhang G; Qu S; Li Y; Feng W; Yang M; Liu B; Ouyang W; Liang J; Yu Z; Kang X; Xue S; Yang G; Yan W; Yang Y; Liu Z; Peng Y; Fanslow B; Huang X; Zhang L; Zhao H
    J Hematol Oncol; 2023 May; 16(1):50. PubMed ID: 37158938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
    Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
    Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
    Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial.
    Cao Y; Lu M; Sun Y; Gong J; Li J; Lu Z; Li J; Zhang X; Li Y; Peng Z; Zhou J; Wang X; Shen L
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):779-789. PubMed ID: 35166929
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
    Patnaik A; Weiss GJ; Rasco DW; Blaydorn L; Mirabella A; Beeram M; Guo W; Lu S; Danaee H; McEachern K; Im E; Sachdev JC
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):93-103. PubMed ID: 34750637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial.
    Heinhuis KM; Carlino M; Joerger M; Di Nicola M; Meniawy T; Rottey S; Moreno V; Gazzah A; Delord JP; Paz-Ares L; Britschgi C; Schilder RJ; O'Byrne K; Curigliano G; Romano E; Patah P; Wang R; Liu Y; Bajaj G; Siu LL
    JAMA Oncol; 2020 Jan; 6(1):100-107. PubMed ID: 31697308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial.
    Fang C; Zhou Y; Feng Y; He L; Yu J; Li Y; Feng M; Pan M; Zhao L; Tang D; Li X; Tan B; An R; Zheng X; Si M; Zhang B; Li L; Kang X; Zhou Q; Liu J
    J Gynecol Oncol; 2024 Mar; ():. PubMed ID: 38606822
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors.
    Borazanci E; Schram AM; Garralda E; Brana I; Vieito Villar M; Spreafico A; Oliva M; Lakhani NJ; Hoffman K; Hallett RM; Maetzel D; Hua F; Hilbert J; Giblin P; Anido J; Kelly A; Vickers PJ; Wasserman R; Seoane J; Siu LL; Hyman DM; Hoff DV; Tabernero J
    ESMO Open; 2022 Aug; 7(4):100530. PubMed ID: 35921760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
    Baranda JC; Robbrecht D; Sullivan R; Doger B; Santoro A; Barve M; Grob JJ; Bechter O; Vieito M; de Miguel MJ; Schadendorf D; Johnson M; Pouzin C; Cantalloube C; Wang R; Lee J; Chen X; Demers B; Amrate A; Abbadessa G; Hodi FS
    Clin Transl Sci; 2024 Jun; 17(6):e13854. PubMed ID: 38898592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
    Strauss J; Deville JL; Sznol M; Ravaud A; Maruzzo M; Pachynski RK; Gourdin TS; Maio M; Dirix L; Schlom J; Donahue RN; Tsai YT; Wang X; Vugmeyster Y; Beier F; Seebeck J; Schroeder A; Chennoufi S; Gulley JL
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37236636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors.
    Geva R; Voskoboynik M; Dobrenkov K; Mayawala K; Gwo J; Wnek R; Chartash E; Long GV
    Cancer; 2020 Nov; 126(22):4926-4935. PubMed ID: 32809217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors.
    Zheng Y; Zhong H; Zhao F; Zhou H; Mao C; Lv W; Yuan M; Qian J; Jiang H; Wang Z; Xiao C; Guo J; Liu T; Liu W; Wang ZM; Li B; Xia M; Xu N
    ESMO Open; 2023 Apr; 8(2):101156. PubMed ID: 36989884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G
    Sheng X; Yan X; Chi Z; Si L; Cui C; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Wang K; Tang X; Zhou H; Wu H; Feng H; Yao S; Flaherty KT; Guo J
    J Clin Oncol; 2019 Nov; 37(32):2987-2999. PubMed ID: 31403867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.